Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 490

1.

A B-cell activating factor receptor (BAFF-R) His159Tyr mutation in Sjögren's Syndrome related lymphoproliferation.

Papageorgiou A, Mavragani CP, Nezos A, Zintzaras E, Quartuccio L, De Vita S, Koutsilieris M, Tzioufas AG, Moutsopoulos HM, Voulgarelis M.

Arthritis Rheumatol. 2015 Jun 19. doi: 10.1002/art.39231. [Epub ahead of print]

PMID:
26097183
2.

Professor Norman Talal 1934-2015.

Moutsopoulos HM, Sugai S, Sawada S, Koike T, Miyasaka N, Kobayashi S, Takei M, Ogawa N.

Mod Rheumatol. 2015 Jul;25(4):664. doi: 10.3109/14397595.2015.1052683. No abstract available.

PMID:
26095110
3.

Clinical and laboratory predictors of distinct histopathogical features of lupus nephritis.

Mavragani CP, Fragoulis GE, Somarakis G, Drosos A, Tzioufas AG, Moutsopoulos HM.

Medicine (Baltimore). 2015 May;94(21):e829. doi: 10.1097/MD.0000000000000829.

PMID:
26020385
4.

Subclinical atherosclerosis and impaired bone health in patients with primary Sjogren's syndrome: prevalence, clinical and laboratory associations.

Gravani F, Papadaki I, Antypa E, Nezos A, Masselou K, Ioakeimidis D, Koutsilieris M, Moutsopoulos HM, Mavragani CP.

Arthritis Res Ther. 2015 Apr 11;17(1):99. doi: 10.1186/s13075-015-0613-6.

5.

Predicting the outcome of Sjogren's syndrome-associated non-hodgkin's lymphoma patients.

Papageorgiou A, Ziogas DC, Mavragani CP, Zintzaras E, Tzioufas AG, Moutsopoulos HM, Voulgarelis M.

PLoS One. 2015 Feb 27;10(2):e0116189. doi: 10.1371/journal.pone.0116189. eCollection 2015.

6.

Adverse events and infections in patients with rheumatoid arthritis treated with conventional drugs or biologic agents: a real world study.

Lampropoulos CE, Orfanos P, Bournia VK, Karatsourakis T, Mavragani C, Pikazis D, Manoussakis MN, Tzioufas AG, Moutsopoulos HM, Vlachoyiannopoulos PG.

Clin Exp Rheumatol. 2015 Mar-Apr;33(2):216-24. Epub 2015 Feb 9.

PMID:
25664400
7.

Impaired clearance of early apoptotic cells mediated by inhibitory IgG antibodies in patients with primary Sjögren's syndrome.

Manoussakis MN, Fragoulis GE, Vakrakou AG, Moutsopoulos HM.

PLoS One. 2014 Nov 14;9(11):e112100. doi: 10.1371/journal.pone.0112100. eCollection 2014.

8.

Reduction of Intraepidermal Nerve Fiber Density (IENFD) in the skin biopsies of patients with fibromyalgia: a controlled study.

Kosmidis ML, Koutsogeorgopoulou L, Alexopoulos H, Mamali I, Vlachoyiannopoulos PG, Voulgarelis M, Moutsopoulos HM, Tzioufas AG, Dalakas MC.

J Neurol Sci. 2014 Dec 15;347(1-2):143-7. doi: 10.1016/j.jns.2014.09.035. Epub 2014 Sep 28.

PMID:
25304055
9.

Impaired degradation and aberrant phagocytosis of necrotic cell debris in the peripheral blood of patients with primary Sjögren's syndrome.

Fragoulis GE, Vakrakou AG, Papadopoulou A, Germenis A, Kanavakis E, Moutsopoulos HM, Manoussakis MN.

J Autoimmun. 2015 Jan;56:12-22. doi: 10.1016/j.jaut.2014.08.004. Epub 2014 Sep 16.

PMID:
25228497
10.

Elevated IgG4 serum levels among primary Sjögren's syndrome patients: do they unmask underlying IgG4-related disease?

Mavragani CP, Fragoulis GE, Rontogianni D, Kanariou M, Moutsopoulos HM.

Arthritis Care Res (Hoboken). 2014 May;66(5):773-7. doi: 10.1002/acr.22216.

PMID:
25100215
11.

IgG4-related disease: a rheumatologist's perspective.

Soliotis F, Mavragani CP, Plastiras SC, Rontogianni D, Skopouli FN, Moutsopoulos HM.

Clin Exp Rheumatol. 2014 Sep-Oct;32(5):724-7. Epub 2014 Jul 28.

PMID:
25068679
12.

Periodic fevers in adult Greeks: clinical and molecular presentation.

Karatsourakis TP, Oikonomaki KN, Tzioufas AG, Moutsopoulos HM.

Clin Exp Rheumatol. 2014 Jul-Aug;32(4 Suppl 84):S45-8. Epub 2014 Apr 7.

PMID:
24708999
13.

Sjögren syndrome.

Mavragani CP, Moutsopoulos HM.

CMAJ. 2014 Oct 21;186(15):E579-86. doi: 10.1503/cmaj.122037. Epub 2014 Feb 24. Review. No abstract available.

PMID:
24566651
14.

Sjögren's syndrome: a forty-year scientific journey.

Moutsopoulos HM.

J Autoimmun. 2014 Jun;51:1-9. doi: 10.1016/j.jaut.2014.01.001. Epub 2014 Jan 29. Review.

PMID:
24485155
15.

Classification criteria of Sjögren's syndrome.

Goules AV, Tzioufas AG, Moutsopoulos HM.

J Autoimmun. 2014 Feb-Mar;48-49:42-5. doi: 10.1016/j.jaut.2014.01.013. Epub 2014 Jan 21. Review.

PMID:
24456935
16.

Clinically significant renal involvement in primary Sjögren's syndrome: clinical presentation and outcome.

Goules AV, Tatouli IP, Moutsopoulos HM, Tzioufas AG.

Arthritis Rheum. 2013 Nov;65(11):2945-53. doi: 10.1002/art.38100.

17.

Absence of somatic MYD88 L265P mutations in patients with primary Sjogren's syndrome.

Voulgarelis M, Mavragani CP, Xu L, Treon SP, Moutsopoulos HM.

Genes Immun. 2014 Jan;15(1):54-6. doi: 10.1038/gene.2013.54. Epub 2013 Oct 24.

PMID:
24153350
18.

Sjögren's syndrome.

Mavragani CP, Moutsopoulos HM.

Annu Rev Pathol. 2014;9:273-85. doi: 10.1146/annurev-pathol-012513-104728. Epub 2013 Sep 18. Review.

PMID:
24050623
19.

Psychological characteristics of systemic sclerosis patients and their correlation with major organ involvement and disease activity.

Golemati CV, Moutsopoulos HM, Vlachoyiannopoulos PG.

Clin Exp Rheumatol. 2013 Mar-Apr;31(2 Suppl 76):37-45. Epub 2013 Jul 22.

PMID:
23910608
20.

Minor salivary gland inflammatory lesions in Sjögren syndrome: do they evolve?

Kapsogeorgou EK, Christodoulou MI, Panagiotakos DB, Paikos S, Tassidou A, Tzioufas AG, Moutsopoulos HM.

J Rheumatol. 2013 Sep;40(9):1566-71. doi: 10.3899/jrheum.130256. Epub 2013 Aug 1.

PMID:
23908448
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk